查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1729635

日本放射治疗市场规模、份额、趋势及预测（按类型、应用、最终用户和地区），2025 年至 2033 年

Japan Radiotherapy Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 122 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024 年日本放射治疗市场规模价值 4.4437 亿美元。展望未来， IMARC Group估计到 2033 年市场规模将达到 7.1947 亿美元，2025 年至 2033 年的复合年增长率为 5.28%。治疗方式的不断突破、强调老年医疗保健的人口趋势、促进先进医疗保健的政策措施、医疗保健投资的快速扩张以及公众对早期干预的认识的不断提高，正在显着影响日本放射治疗市场份额。

日本市场主要受到能够实现更准确、更有针对性的放射治疗的进步和创新的推动。例如，2024年5月30日，日本国家量子科学技术研究所（QST）宣布成功透过雷射照射产生高能量电子束，这项突破可望改善放射癌症治疗。此项开发利用微毛细管板产生高效率电子束，可减少辐射暴露并消除屏蔽的需要。这项创新为低成本内视镜放射治疗铺平了道路，并有望应用于癌症治疗。除此之外，人工智慧 (AI) 和机器学习在放射治疗计划和实施中的整合优化了治疗工作流程和结果，为市场提供了动力。此外，日本拥有高技能的医疗专业人员和完善的医疗保健系统，确保这些治疗能够有效率地进行，从而促进市场扩张。此外，领先企业和学术机构正在进行的研究和开发 (R&D) 活动正在促进放射治疗领域的创新，丰富日本放射治疗市场的前景。

此外，包括专门的肿瘤中心在内的医疗保健基础设施的投资不断增加，使得全国各地都能轻鬆获得放射治疗服务。此外，大众对早期癌症诊断和治疗方案的认识不断提高，导致产品使用率更高。除此之外，国内外公司的合作正在促进技术进步和市场竞争力，从而确保日本放射治疗解决方案的可用性。例如，2024 年 1 月 17 日，Vysioneer 宣布与 MC Medical 达成策略合作，将其基于人工智慧的脑肿瘤自动勾画解决方案 VBrain 引入日本市场。此次合作旨在利用人工智慧技术增强临床工作流程并提高脑肿瘤管理的​​治疗精度。 VBrain 旨在简化临床工作流程并提高脑放射外科和放射治疗的治疗准确性，从而显着减少工作量并提高患者护理品质。

日本放射治疗市场趋势：

癌症发生率上升和人口老化

癌症发生率的不断上升，尤其是在日本老龄化人口中，正在影响日本放射治疗市场的成长。日本国立医学图书馆的一项研究表明，日本癌症的总体发病率可能会上升。预计到 2050 年，新发病例总数将达到 3,665,900（3,210,200 至 4,201,400）千例，比 2020 年增加 13.1%。人口趋势也增加了医疗基础设施投资和重要放射治疗技术的实施。这一增长也归因于75岁及以上老年人口的增长。罹患癌症的风险会随着年龄的增长而增加，因此对放射治疗等更先进的治疗方式的需求也在增加。这些治疗的进步旨在提高治疗的精确度、最大限度地减少副作用并满足老年患者的独特需求。

放射治疗设备的技术进步

技术进步正在显着提升日本放射治疗市场的份额。影像导引放射治疗 (IGRT)、调强放射治疗 (IMRT)、立体定位放射治疗 (SBRT) 等放射治疗设备创新提高了治疗的准确性，同时减少了对周围组织的损伤。日本在质子和重离子治疗系统的开发方面处于领先地位，这些系统对复杂的肿瘤治疗非常有效。这些创新透过将患者与政府加强内部医疗保健能力的措施相结合，满足了患者日益增长的需求。例如，2024年，日立高新技术推出了OXRAY，这是一款X射线治疗系统，旨在减轻患者负担，同时为癌症提供精准的放射治疗。该系统的便携式设计允许安装在专门的医疗中心和地区医院，为癌症治疗带来精确性和高品质。日立高新技术正在开发先进的粒子束系统和加速器，用于高精度、低成本的治疗，进一步增强患者友善、高精度的癌症治疗。随着越来越多的医院和癌症中心利用这些创新，这些发展推动了市场需求。

政府政策和医疗基础设施扩张

医疗政策和基础设施投资影响日本放射治疗市场趋势。日本主要透过《癌症控制法》致力于癌症患者的护理，强调早期发现、标准化治疗和采用先进技术。政府投入大量资金更新医疗保健结构并增加癌症专门治疗的可用性。这些措施得到了厚生劳动省的支持，以促进临床试验和研究，从而推动放射治疗的创新发展。战略合作伙伴关係促进了先进放射治疗技术的应用，并推动了支持市场扩张的投资。例如，2024 年 9 月 24 日，国际原子能总署 (IAEA)、宏都拉斯和日本政府透过国际原子能总署的「希望之光」倡议合作，促进洪都拉斯的癌症治疗。此次合作将增加放射治疗服务，并扩大宏都拉斯获得挽救生命的癌症诊断和治疗的机会。为此，日本政府表示有兴趣提供设施、设备和基础设施。同时，国际原子能总署将提供技术咨询服务，促进该国增加放射学、核子医学和放射治疗设施。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本放射治疗市场-简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本放射治疗市场格局

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第六章：日本放射治疗市场-分类：依类型

  • 体外放射治疗
    • 概述
    • 市场区隔
      • 调强放射治疗 (IMRT)
      • 影像导引放射治疗 (IGRT)
      • 断层治疗
      • 立体定位放射外科
      • 立体定位放射治疗
      • 质子治疗
      • 3D适形放射治疗（3D CRT）
      • 容积调强弧形治疗 (VMAT)
  • 内部放射治疗/近距离放射治疗
    • 概述
  • 全身放射治疗
    • 概述

第七章：日本放射治疗市场-细分：依应用

  • 皮肤和唇癌
    • 概述
  • 头颈癌
    • 概述
  • 乳癌
    • 概述
  • 摄护腺癌
    • 概述
  • 子宫颈癌
    • 概述
  • 肺癌
    • 概述
  • 其他的

第 8 章：日本放射治疗市场 - 细分：按最终用户

  • 医院
    • 概述
  • 癌症研究机构
    • 概述
  • 门诊及放射治疗中心
    • 概述

第九章：日本放射治疗市场-竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第十章：关键参与者简介

  • Elekta K.K. (Elekta)
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Hitachi Ltd.
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Osaka Heavy Ion Therapy Center
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Sumitomo Heavy Industries Ltd.
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Toshiba Corporation
    • Business Overview
    • Services Offered
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 11 章：日本放射治疗市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 12 章：附录

简介目录
Product Code: SR112025A18341

The Japan radiotherapy market size was valued at USD 444.37 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 719.47 Million by 2033, exhibiting a CAGR of 5.28% from 2025-2033. Continual breakthroughs in treatment modalities, demographic trends emphasizing senior healthcare, policy measures promoting advanced medical care, rapid expansion of healthcare investments, and the growing public awareness regarding early interventions are impacting the Japan radiotherapy market share significantly.

The market in Japan is primarily driven by the advancements and innovations that enable more accurate and targeted radiotherapy. For example, on May 30, 2024, the National Institute for Quantum Science and Technology (QST) announced the successful generation of high-energy electron beams via laser irradiation, a breakthrough expected to improve radiation cancer treatment. This development uses microcapillary plates to produce efficient electron beams, which could reduce radiation exposure and eliminate the need for shielding. The innovation paves the way for low-cost, endoscopic radiation therapy with potential applications in cancer treatment. Besides this, the integration of artificial intelligence (AI) and machine learning in radiotherapy planning and delivery has optimized treatment workflows and outcomes, which is providing an impetus to the market. Furthermore, the presence of highly skilled medical professionals and a well-established healthcare system in Japan ensures efficient delivery of these treatments, which is facilitating market expansion. Also, ongoing research and development (R&D) activities by leading players and academic institutions are fostering innovations in radiotherapy is enriching the Japan radiotherapy market outlook.

In addition to this, the increasing investments in healthcare infrastructure, including specialized oncology centers, are enabling easy accessibility of radiotherapy services across the country. Moreover, the rising awareness among the public regarding early cancer diagnosis and treatment options is leading to a higher product uptake. Apart from this, collaborations between domestic and international companies are encouraging technological advancements and market competitiveness, thereby ensuring the availability of radiotherapy solutions in Japan. For instance, on January 17, 2024, Vysioneer announced a strategic collaboration with MC Medical to introduce its AI-powered brain tumor auto-contouring solution, VBrain, to the Japanese market. This partnership aims to enhance clinical workflows and improve treatment precision in brain tumor management by leveraging AI technology. VBrain is designed to streamline clinical workflows and elevate treatment accuracy for brain radiosurgery and radiotherapy, offering significant reductions in workload and improvements in patient care quality.

Japan Radiotherapy Market Trends:

Rising Prevalence of Cancer and Aging Population

The increasing incidence of cancer, especially among Japan's aging population, is impacting the Japan radiotherapy market growth. A research conducted by the National Library of Medicine indicates that the overall incidence of cancer in Japan is likely to rise. It estimates a total of 3,665,900 (3,210,200 to 4,201,400) thousand new cases by 2050, indicating a 13.1% increase from the year 2020. The demographic trend has also increased healthcare infrastructure investment and the implementation of significant radiotherapy technologies. The increase is also attributed to aging people aged 75 years and older. The risk of cancer increases with age, and thus, the demand for more advanced treatment modalities, such as radiotherapy, is increasing. These advances in treatment are meant to improve precision, minimize side effects, and cater to the unique needs of older patients.

Technological Advancements in Radiotherapy Equipment

Technological progress is significantly rising the Japan radiotherapy market share. Radiotherapy equipment innovations such as image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and stereotactic body radiotherapy (SBRT) improve the accuracy of treatment while reducing damage to surrounding tissues. Japan leads the way in developing proton and heavy ion therapy systems, which are highly effective in complex tumor treatments. The innovations cater to the increasing requirements of patients by aligning them with government measures to enhance internal healthcare capabilities. For instance, in 2024, Hitachi High-Tech released OXRAY, an X-ray therapy system designed to reduce patient burdens while delivering accurate radiation treatment for cancer. The portable design of this system allows installation at specialized medical centers and regional hospitals, bringing precision and quality to cancer treatments. Hitachi High-Tech is developing advanced particle beam systems and an accelerator for high-precision, low-cost treatments, further enhancing patient-friendly, high-precision cancer therapies. These developments drive the market demand as more hospitals and cancer centers leverage these innovations.

Government Policies and Healthcare Infrastructure Expansion

Healthcare policies and infrastructural investments influence Japan radiotherapy market trends. Japan mainly focuses its efforts on the care of cancer patients through its Cancer Control Act, underlining early detection, standardization of treatment, and the adoption of advanced technology. The government invests heavily in updating healthcare structures and increasing the availability of specialized treatments for cancer. These initiatives are followed by the support given by the Ministry of Health, Labour, and Welfare in promoting clinical trials and research, hence the development of innovations in radiotherapy. Strategic partnerships foster the adoption of advanced radiotherapy technologies and drive investments that support market expansion. For instance, on 24 September 2024, the International Atomic Energy Agency (IAEA), Honduras, and the Government of Japan collaborated to promote cancer care in Honduras through the IAEA's Rays of Hope initiative. This collaboration will increase radiotherapy services and extend access to lifesaving cancer diagnosis and treatment in Honduras. For this, the government of Japan has expressed its interest to contribute with facilities, equipment, and infrastructures. At the same time, the IAEA will provide technical advisory services to foster an increase in the country's facilities for radiology, nuclear medicine, and radiotherapy.

Japan Radiotherapy Industry Segmentation:

Analysis by Type:

  • External Beam Radiation Therapy
    • Intensity-Modulated Radiation Therapy (IMRT)
    • Image-Guided Radiation Therapy (IGRT)
    • Tomotherapy
    • Stereotactic Radiosurgery
    • Stereotactic Body Radiation Therapy
    • Proton Therapy
    • 3D Conformal Radiotherapy (3D CRT)
    • Volumetric Modulated Arc Therapy (VMAT)
  • Internal Radiation Therapy/Brachytherapy
  • Systemic Radiation Therapy

External beam radiation therapy (EBRT) is a significant segment in the radiation therapy market in Japan. EBRT helps give high-energy beams targeted toward tumors but minimizes damage to other tissues around it. Advances like intensity-modulated radiation therapy (IMRT) and SBRT are gradually used for greater precision and decreased side effects of radiation. Japan's investment in cutting-edge linear accelerators and image-guided technologies enhances treatment outcomes. With an aging population and increasing cancer incidence, EBRT remains essential in expanding access to non-invasive and effective treatment solutions.

Brachytherapy is one of the key components of radiotherapy advancements in Japan, especially for cervical, prostate, and breast cancers. The radioactive sources are placed directly inside or near the tumor, delivering high doses of radiation to the target while sparing healthy tissues. This approach allows for shorter treatment durations and fewer hospital visits, appealing to patient preferences. Japan's adoption of image-guided brachytherapy (IGBT) has significantly improved accuracy and outcomes. Government-sponsored programs to incorporate brachytherapy into overall cancer treatment emphasize the role of brachytherapy, especially in areas where high-tech external beam technologies are scarce.

Systemic radiation therapy, including radiopharmaceuticals, has been increasingly adopted in Japan, especially for metastatic cancers. The therapy is delivered through radioactive drugs that circulate in the bloodstream to reach the cancer cells. Lutetium-177 and Iodine-131 are the most common radionuclides used for prostate and thyroid cancers, respectively. In Japan, improvements in the regulatory side have allowed more rapid approvals for radiopharmaceuticals, thus growing the market. Systemic therapy would represent a minimally invasive treatment modality with specificity, as advocated by personalized medicine in Japan, improving patient quality of life.

Analysis by Application:

  • Skin and Lip Cancer
  • Head and Neck Cancer
  • Breast Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Lung Cancer
  • Others

Radiotherapy plays an important role in the management of skin and lip cancer in Japan, especially non-melanoma types such as basal cell carcinoma and squamous cell carcinoma. For tumors in cosmetically sensitive areas, external beam radiation therapy (EBRT) is widely used to avoid surgery. Techniques like superficial X-ray therapy and brachytherapy provide targeted therapy with minimal scarring and excellent aesthetic results. The management is effective due to the increasing awareness regarding early diagnosis and the availability of advanced technologies.

Radiotherapy is significant in the treatment of head and neck cancers in Japan, and is usually combined with chemotherapy or surgery to achieve better results. These cancers, involving the oral cavity, pharynx, and larynx, need specific targeting to conserve vital structures. Technologies such as intensity-modulated radiation therapy and image-guided radiation therapy have become widely used, where the tumor would be controlled in the least aggressive manner possible in terms of side effects such as xerostomia and swallowing difficulty. Japan also invests in proton therapy in support of good care.

Radiotherapy is used in Japan after lumpectomy as the first treatment course for breast cancer, minimizing the risks of recurrence. It also applies different techniques like whole-breast irradiation and APBI tailored to each patient, achieving efficient tumor control while avoiding excessive damage to normal tissues. Advanced technologies employed include 3D conformal radiation and proton therapy, which take accurate targeting, more so for left-sided breast cancer exposure on the heart. The rise in breast cancer diagnoses in Japan is one of the major Japan radiotherapy market trends that are leading to increased investment in radiotherapy infrastructure to drive the care of the disease and thus increase survival rates.

Analysis by End User:

  • Hospitals
  • Cancer Research Institutes
  • Ambulatory and Radiotherapy Centers

Hospitals are the biggest players in Japan's radiotherapy market. As a single point stop for all cancer treatment needs, hospitals have well-equipped technologies like linear accelerators and proton therapy systems. These centers provide high-quality care to patients through the administration of EBRT and brachytherapy, thus being able to guarantee accuracy and patient safety. Since cancer is one of the leading causes of death in Japan, hospitals increasingly integrate radiotherapy with surgical and systemic treatments. Government investments in public hospitals to expand radiotherapy infrastructure and improve accessibility underline their central role in meeting the growing demand for advanced cancer care.

Radiotherapy technologies and techniques are advanced in Japan by research institutes dedicated to cancer. Such institutes are oriented toward clinical trials, including novel approaches such as proton and carbon-ion therapy and personalized medicine solutions. Their contribution increases the effectiveness of treatment, reduces side effects, and enhances survival rates. Collaboration with academic and industrial partners propels innovative radiopharmaceuticals and diagnostic tools into the future. These institutes support Japan's leadership in radiotherapy innovation and contribute to global advancements in cancer treatment strategies by training specialized professionals and conducting research on treatment optimization.

Ambulatory and radiotherapy centers are growing in popularity in Japan, catering to the needs of accessible, specialized cancer care. These are outpatient centers, thus reducing pressure on hospitals and, at the same time, providing high-quality care. They are fitted with the most advanced systems of EBRT and brachytherapy, so precise and efficient care is assured. Their operations are streamlined, and the treatment is shorter, a factor that attracts patients who desire convenience. Also, due to the increasing incidence of cancer and an aging population, these centers will be crucial for decentralizing care and meeting the demand, particularly in areas that lack comprehensive hospital facilities.

Competitive Landscape:

The market in Japan is highly competitive, majorly driven by technological advancements and innovation. Key players focus more on the development of precision-based radiotherapy systems such as proton and carbon ion therapy to address the increasing cancer burden. Higher investments in research and development (R&D) activities and healthcare infrastructure expansion also intensify competition. Strategic partnerships among healthcare institutions and technology developers help to foster innovation and accelerate the adoption of next-generation radiotherapy equipment. These partnerships improve accessibility to advanced treatments while ensuring market growth. For instance, on 31 October 2024, Leo Cancer Care announced a partnership with Anzai Medical Co., Ltd, making Anzai the official distributor of Leo's upright radiation therapy systems in Japan. This collaboration aims to enhance patient comfort and treatment efficiency by introducing new systems, which include the Marie upright particle therapy solution. The partnership will provide Japanese healthcare providers with state-of-the-art, adaptable radiation therapy technologies in line with the commitment of both companies to enhance cancer care.

The report provides a comprehensive analysis of the competitive landscape in the Japan radiotherapy market with detailed profiles of all major companies, including:

  • Elekta K.K. (Elekta)
  • Hitachi Ltd.
  • Osaka Heavy Ion Therapy Center
  • Sumitomo Heavy Industries Ltd.
  • Toshiba Corporation

Latest News and Developments:

  • April 17, 2024: Japan's National Institutes for Quantum Science and Technology (QST) initiated multi-ion heavy particle radiotherapy to enhance cancer treatment, particularly for bone and soft-tissue sarcoma. This next-generation technology combines ion beams like carbon, oxygen, and helium for tailored treatment, reducing side effects and improving efficacy. The development, achieved in collaboration with Sumitomo Heavy Industries, builds on three decades of advancements and positions Japan as a leader in radiotherapy innovation.
  • June 18, 2024: RaySearch Laboratories' RayStation was used for the world's first clinical radiotherapy treatment with Hitachi's OXRAY system at Narita Memorial Hospital in Toyohashi, Japan. OXRAY, developed in collaboration with Kyoto University Hospital, integrates a Gimbal-mounted beam delivery system and advanced motion tracking capabilities, improving precision and flexibility in radiotherapy. This milestone highlights the synergy between RaySearch's planning software and OXRAY's innovative technology, promising enhanced treatment outcomes.
  • June 27, 2024: Yamagata University's East Japan Heavy Ion Center, offering advanced carbon-ion radiation therapy, is becoming a key hub for medical tourism. The facility specializes in treating various cancers with minimal side effects, attracting both domestic and international patients. The center is expanding its collaborations with local businesses to offer tailored travel and treatment packages, boosting the region's economy through medical tourism.
  • September 25, 2024: Leo Cancer Care announced a new research partnership with QST Hospital in Japan to test its upright positioning system for cancer treatment. This collaboration aims to evaluate patient comfort, reproducibility, and immobilization across various anatomical regions, with a focus on advancing carbon ion radiotherapy. The partnership follows similar agreements in Japan and Italy, marking significant progress in the development of upright radiotherapy solutions.

Key Questions Answered in This Report

  • 1.How big is the radiotherapy market in Japan?
  • 2.What factors are driving the growth of Japan radiotherapy market?
  • 3.What is the forecast for the radiotherapy market in Japan?
  • 4.Who are the major players in the radiotherapy market in Japan?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Radiotherapy Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Radiotherapy Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Radiotherapy Market - Breakup by Type

  • 6.1 External Beam Radiation Therapy
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Intensity-Modulated Radiation Therapy (IMRT)
      • 6.1.3.2 Image-Guided Radiation Therapy (IGRT)
      • 6.1.3.3 Tomotherapy
      • 6.1.3.4 Stereotactic Radiosurgery
      • 6.1.3.5 Stereotactic Body Radiation Therapy
      • 6.1.3.6 Proton Therapy
      • 6.1.3.7 3D Conformal Radiotherapy (3D CRT)
      • 6.1.3.8 Volumetric Modulated Arc Therapy (VMAT)
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Internal Radiation Therapy/Brachytherapy
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Systemic Radiation Therapy
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)

7 Japan Radiotherapy Market - Breakup by Application

  • 7.1 Skin and Lip Cancer
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Head and Neck Cancer
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Breast Cancer
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)
  • 7.4 Prostate Cancer
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2019-2024)
    • 7.4.3 Market Forecast (2025-2033)
  • 7.5 Cervical Cancer
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2019-2024)
    • 7.5.3 Market Forecast (2025-2033)
  • 7.6 Lung Cancer
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2019-2024)
    • 7.6.3 Market Forecast (2025-2033)
  • 7.7 Others
    • 7.7.1 Historical and Current Market Trends (2019-2024)
    • 7.7.2 Market Forecast (2025-2033)

8 Japan Radiotherapy Market - Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Cancer Research Institutes
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Ambulatory and Radiotherapy Centers
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)

9 Japan Radiotherapy Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Elekta K.K. (Elekta)
    • 10.1.1 Business Overview
    • 10.1.2 Services Offered
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Hitachi Ltd.
    • 10.2.1 Business Overview
    • 10.2.2 Services Offered
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Osaka Heavy Ion Therapy Center
    • 10.3.1 Business Overview
    • 10.3.2 Services Offered
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Sumitomo Heavy Industries Ltd.
    • 10.4.1 Business Overview
    • 10.4.2 Services Offered
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Toshiba Corporation
    • 10.5.1 Business Overview
    • 10.5.2 Services Offered
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Radiotherapy Market - Industry Analysis

  • 11.1 Drivers, Restraints and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix